Impact of β-hydroxy-β-methylbutyrate (HMB) on muscle loss and protein metabolism in critically ill patients: A RCT.
Aged
Amino Acids
/ blood
Body Composition
Critical Illness
/ therapy
Dietary Supplements
Double-Blind Method
Electric Impedance
Enteral Nutrition
Female
Humans
Intensive Care Units
Male
Middle Aged
Muscle, Skeletal
/ diagnostic imaging
Muscular Atrophy
/ etiology
Organ Dysfunction Scores
Prospective Studies
Quadriceps Muscle
/ diagnostic imaging
Ultrasonography
/ methods
Valerates
/ administration & dosage
Critically ill
Glucose
Protein metabolism
Journal
Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
31
05
2021
revised:
08
07
2021
accepted:
13
07
2021
pubmed:
7
8
2021
medline:
28
12
2021
entrez:
6
8
2021
Statut:
ppublish
Résumé
Muscle wasting deteriorates life quality after critical illness and increases mortality. Wasting starts upon admission to intensive care unit (ICU). We aimed to determine whether β-hydroxy-β-methylbutyrate (HMB), a metabolite of leucine, can attenuate this process. Prospective randomized, placebo-controlled double blind trial. ICU patients depending on mechanical ventilation on day 3 having a functional gastrointestinal tract. They were randomized to HMB (3 g/day) or placebo (maltodextrin) from day 4 on for 30 days. magnitude of loss of skeletal muscle area (SMA) of the quadriceps femoris measured by ultrasound at days 4 and 15. body composition, change in protein metabolism assessed by amino acids tracer pulse, and global health at 60 days. Data are mean [95% CI]. Statistics by ANCOVA with correction for confounders sex, age and/or BMI. Thirty patients completed the trial, aged 65 [59, 71] years, SAPS2 score 48 [43, 52] and SOFA 8.5 [7.4, 9.7]. The loss of total SMA was 11% between days 4 and 15 (p < 0.001), but not different between the groups (p = 0.86). In the HMB group, net protein breakdown (Δ Estimate HMB-Placebo: -153 [-242, -63]; p = 0.0021) and production of several amino acid was significantly reduced, while phase angle increased more (0.66 [0.09, 1.24]; p = 0.0247), and SF-12 global health improved more (Δ Estimate HMB-Placebo: 27.39 [1.594, 53.19], p = 0.04). HMB treatment did not significantly reduce muscle wasting over 10 days of observation (primary endpoint), but resulted in significantly improved amino acid metabolism, reduced net protein breakdown, a higher phase angle and better global health. CLINICALTRIALS. NCT03628365.
Identifiants
pubmed: 34358832
pii: S0261-5614(21)00352-6
doi: 10.1016/j.clnu.2021.07.018
pii:
doi:
Substances chimiques
Amino Acids
0
Valerates
0
beta-hydroxyisovaleric acid
3F752311CD
Banques de données
ClinicalTrials.gov
['NCT03628365']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4878-4887Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest MBB: no COI related to the present study. MMB receives honoraria for lectures from ABBOTT, Baxter, BBraun, DSM, Fresenius Kabi, Nestlé, Nutricia. NEPD receives honoraria for lectures from ABBOTT Nutrition.